Pharmacological thiamine levels as a therapeutic approach in Alzheimer's disease by Gary E. Gibson, Howard H. Feldman, Sheng Zhang, Sarah A. Flowers, José A. Luchsinger

Get full text

Evaluation of bumetanide as a potential therapeutic agent for Alzheimer’s disease by Ben Boyarko, Sonia Podvin, Barry Greenberg, Jeremiah D. Momper, Yadong Huang, Yadong Huang, William H. Gerwick, William H. Gerwick, Anne G. Bang, Luisa Quinti, Ana Griciuc, Doo Yeon Kim, Rudolph E. Tanzi, Howard H. Feldman, Howard H. Feldman, Vivian Hook, Vivian Hook

Get full text

Developing the Healthy Actions and Lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia program by Sara Moukarzel, Zvinka Z. Zlatar, Sheri J. Hartman, Derek Lomas, Howard H. Feldman, Sarah J. Banks, HALT‐AD Study Group

Get full text

evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomat... by Jeffrey L. Cummings, Alireza Atri, Howard H. Feldman, Oskar Hansson, Mary Sano, Filip K. Knop, Peter Johannsen, Teresa León, Philip Scheltens

Get full text

Enriching the design of Alzheimer's disease clinical trials: Application of the polygenic hazard score and composite outcome measures by Sarah J. Banks, Yuqi Qiu, Chun Chieh Fan, Anders M. Dale, Jingjing Zou, Brianna Askew, Howard H. Feldman, For the Alzheimer's Disease Neuroimaging Initiative

Get full text

Efficacy assessment of an active tau immunotherapy in Alzheimer’s disease patients with amyloid and tau pathology: a post hoc analysis of the “ADAMANT” randomised, placebo-controll... by Nicholas C. Cullen, Petr Novak, Duygu Tosun, Branislav Kovacech, Jozef Hanes, Eva Kontsekova, Michal Fresser, Stefan Ropele, Howard H. Feldman, Reinhold Schmidt, Bengt Winblad, Norbert Zilka

Get full text

Personal value of Alzheimer's disease biomarker testing and result disclosure from the patient and care partner perspective by Khushbu J. Patel, David Yang, Howard H. Feldman, Ging‐Yuek R. Hsiung, Haakon B. Nygaard, John R. Best, Emily Dwosh, Julie M. Robillard, Mari L. DeMarco

Get full text

Home EEG sleep assessment shows reduced slow‐wave sleep in mild–moderate Alzheimer's disease by Brianne A. Kent, Amelia A. Casciola, Sebastiano K. Carlucci, Meghan Chen, Sam Stager, Maryam S. Mirian, Penelope Slack, Jason Valerio, Martin J. McKeown, Howard H. Feldman, Haakon B. Nygaard

Get full text

Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217 by Branislav Kovacech, Nicholas C. Cullen, Petr Novak, Jozef Hanes, Eva Kontsekova, Stanislav Katina, Vojtech Parrak, Michal Fresser, Jeroen Vanbrabant, Howard H. Feldman, Bengt Winblad, Erik Stoops, Eugeen Vanmechelen, Norbert Zilka

Get full text

Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia by Dawn C. Matthews, Aaron Ritter, Ronald G. Thomas, Randolph D. Andrews, Ana S. Lukic, Carolyn Revta, Jefferson W. Kinney, Babak Tousi, James B. Leverenz, Howard Fillit, Kate Zhong, Howard H. Feldman, Jeffrey Cummings

Get full text

A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Pos... by Douglas Galasko, Martin R. Farlow, Brendan P. Lucey, Lawrence S. Honig, Donald Elbert, Randall Bateman, Jeremiah Momper, Ronald G. Thomas, Robert A. Rissman, Judy Pa, Vahan Aslanyan, Archana Balasubramanian, Tim West, Maria Maccecchini, Howard H. Feldman

Get full text

Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients by Dawn C. Matthews, Jefferson W. Kinney, Aaron Ritter, Randolph D. Andrews, Erin N. Toledano Strom, Ana S. Lukic, Lauren N. Koenig, Carolyn Revta, Howard M. Fillit, Kate Zhong, Babak Tousi, James B. Leverenz, Howard H. Feldman, Jeffrey Cummings

Get full text

Clinical value of Alzheimer's disease biomarker testing by Khushbu J. Patel, David Yang, John R. Best, Colleen Chambers, Philip E. Lee, Alexandre Henri‐Bhargava, Clark R. Funnell, Dean J. Foti, Jacqueline A. Pettersen, Howard H. Feldman, Haakon B. Nygaard, Ging‐Yuek R. Hsiung, Mari L. DeMarco

Get full text

T2 Protect AD: Achieving a rapid recruitment timeline in a multisite clinical trial for individuals with mild to moderate Alzheimer's disease by Aladdin H. Shadyab, Andrea Z. LaCroix, Genevieve Matthews, Daniel Bennett, Alexandre A. Shadyab, Donna Tan, Ronald G. Thomas, Jennifer Mason, Alex Lopez, Brianna Askew, Lia Donahue, Stephen Kaplita, Irfan A. Qureshi, Branko Huisa, Howard H. Feldman, for the Alzheimer's Disease Cooperative Study T2 Protect AD Study Group

Get full text

Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer’s di... by Howard H. Feldman, José A. Luchsinger, Gabriel C. Léger, Curtis Taylor, Diane M. Jacobs, David P. Salmon, Steven D. Edland, Karen Messer, Carolyn Revta, Sarah A. Flowers, Kerry S. Jones, Albert Koulman, Kevin E. Yarasheski, Philip B. Verghese, Venky Venkatesh, Henrik Zetterberg, January Durant, Jody-Lynn Lupo, Gary E. Gibson

Get full text

Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer's di... by Howard H Feldman, José A Luchsinger, Gabriel C Léger, Curtis Taylor, Diane M Jacobs, David P Salmon, Steven D Edland, Karen Messer, Carolyn Revta, Sarah A Flowers, Kerry S Jones, Albert Koulman, Kevin E Yarasheski, Philip B Verghese, Venky Venkatesh, Henrik Zetterberg, January Durant, Jody-Lynn Lupo, Gary E Gibson, ADCS BenfoTeam Study Group

Get full text